Thomas X. Neenan

Thomas X. Neenan is a business leader in the biotech industry with over 20 years of experience in business operations, strategy, and development. Thomas is currently a scientific advisory board member at Adaptilens, a company that specializes in the treatment of presbyopia, or age-related farsightedness.

Neenan began their career in 2000 as VP of Business Operations at Genzyme Drug Discovery and Development. Thomas left Genzyme in 2004 to become Chief Business Officer at The Medicinal Bioconvergence Research Institute of Seoul National University, where they oversaw a $100M development consortium focused on oncology and fibrotic disease therapies. In 2013, Neenan founded Sideris Pharmaceuticals, a biopharmaceutical company focused on the development of new treatments for transfusion related iron overload. Sideris successfully completed a $32 million Series A equity financing in Oct. 2013. In February 2013, Neenan became Co-Founder and CSO of Panbela Therapeutics (NASDAQ: PBLA), a company that specializes in the development of novel therapeutics to treat cancer and other serious diseases. Thomas served as President and CEO of Viscus Biologics from December 2011 to April 2013, and as Vice President of Business Development at Proxy Biomedical from October 2009 to December 2011.

Thomas X. Neenan received their B.Sc (Hons) in Chemistry from University College Dublin. Thomas then went on to receive their Ph.D. in Chemistry from Penn State University. After completing their Ph.D., Neenan became a Post-Doctoral Fellow in Materials Chemistry with George Whitesides at Harvard University.